^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    APVAC1 vaccine

    i
    Other names: APVAC1 vaccine
    Associations

    News

    Trials
    Company:
    BioNTech, Immatics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. (PubMed, Int J Gen Med)
    The GAPVAC-101 trial reported 50% APVAC1-induced and 84.7% APVAC2-induced immunogenicity with CD8+ and CD4+ T cell responses in 92% (12/13) and 80% (8/10) immune responders, respectively...Dexamethasone use had limited immunogenicity in a trial by Keskin et al (6/8)...Actively personalized vaccines aimed at unmutated peptides and neoantigens for patients with GBM are safe and highly immunogenic, particularly when administered in combination. Larger studies are warranted to investigate the role.
    Clinical • Review • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    APVAC1 vaccine